The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

We came across a bullish thesis on Eli Lilly and Company (LLY ... which is set to expand into new therapeutic areas. Despite increasing competition, the company remains strong in both the U.S ...

obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location. Eli Lilly and Company (NYSE ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY ...

And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro and ...

In Q4 2024, Eli Lilly’s top-performing drugs included Mounjaro, which saw a 60% increase in revenue, and Zepbound, which is set to expand into new therapeutic areas. Despite increasing competition, ...